Online citations, reference lists, and bibliographies.
← Back to Search

What Is New In Uremic Toxicity?

R. Vanholder, S. Van Laecke, G. Glorieux
Published 2008 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Uremic syndrome results from a malfunctioning of various organ systems due to the retention of compounds which, under normal conditions, would be excreted into the urine and/or metabolized by the kidneys. If these compounds are biologically active, they are called uremic toxins. One of the more important toxic effects of such compounds is cardio-vascular damage. A convenient classification based on the physico-chemical characteristics affecting the removal of such compounds by dialysis is: (1) small water-soluble compounds; (2) protein-bound compounds; (3) the larger “middle molecules”. Recent developments include the identification of several newly detected compounds linked to toxicity or the identification of as yet unidentified toxic effects of known compounds: the dinucleotide polyphosphates, structural variants of angiotensin II, interleukin-18, p-cresylsulfate and the guanidines. Toxic effects seem to be typically exerted by molecules which are “difficult to remove by dialysis”. Therefore, dialysis strategies have been adapted by applying membranes with larger pore size (high-flux membranes) and/or convection (on-line hemodiafiltration). The results of recent studies suggest that these strategies have better outcomes, thereby clinically corroborating the importance attributed in bench studies to these “difficult to remove” molecules.
This paper references
10.1159/000168447
Suppressed serum and urine levels of indoxyl sulfate by oral sorbent in experimental uremic rats.
T. Niwa (1992)
10.1159/000168716
Progression of glomerular sclerosis in experimental uremic rats by administration of indole, a precursor of indoxyl sulfate.
T. Niwa (1994)
10.1172/JCI117992
Regulation of rat mesangial cell growth by diadenosine phosphates.
S. Heidenreich (1995)
10.1038/KI.1996.441
Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters. The Italian Cooperative Dialysis Study Group.
F. Locatelli (1996)
10.1038/KI.1996.186
Advanced oxidation protein products as a novel marker of oxidative stress in uremia.
V. Witko-Sarsat (1996)
10.1111/J.1474-8673.1996.TB00045.X
Adenine dinucleotides: a novel class of signalling molecules.
A. Ogilvie (1996)
10.1038/KI.1997.434
Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients.
Y. Koda (1997)
10.1038/KI.1997.497
Reduction of plasma apolipoprotein-B by effective removal of circulating glycation derivatives in uremia.
S. Fishbane (1997)
Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure.
V. Witko-Sarsat (1998)
10.1159/000013317
Remarkable Removal of Beta-2-Microglobulin by On-Line Hemodiafiltration
W. Lornoy (1998)
10.1046/J.1525-1594.1998.06072.X
Principles and practice of hemofiltration and hemodiafiltration.
I. Ledebo (1998)
The effect of membrane permeability on ESRD: design of a prospective randomised multicentre trial.
F. Locatelli (1999)
10.1046/j.1523-1755.1999.00236.x
Clinical Nephrology – Epidemiology – Clinical TrialsComparison of mortality in ESRD patients on convective and diffusive extracorporeal treatments
F. Locatelli (1999)
10.1046/J.1523-1755.1999.00236.X
Comparison of mortality in ESRD patients on convective and diffusive extracorporeal treatments. The Registro Lombardo Dialisi E Trapianto.
F. Locatelli (1999)
10.1159/000029849
A Qualitative Estimate of the Influence of Halcinonide Concentration and Urea on the Reservoir Formation in the Stratum Corneum
P. Clarys (1999)
10.1016/S0272-6386(99)70311-2
Effect of dialysis membranes and middle molecule removal on chronic hemodialysis patient survival.
J. Leypoldt (1999)
Pathophysiologic effects of uremic retention solutes.
R. Vanholder (1999)
10.1093/OXFORDJOURNALS.NDT.A027962
Improved outcome for haemodialysis patients treated with high-flux membranes.
H. F. Woods (2000)
10.1093/NDT/15.11.1773
An oral sorbent reduces overload of indoxyl sulphate and gene expression of TGF-beta1 in uraemic rat kidneys.
T. Miyazaki (2000)
10.1093/NDT/15.1.50
Intradialytic removal of protein-bound uraemic toxins: role of solute characteristics and of dialyser membrane.
G. Lesaffer (2000)
beta(2)-microglobulin kinetics in nocturnal haemodialysis.
D. Raj (2000)
10.1093/NDT/15.1.58
β2-Microglobulin kinetics in nocturnal haemodialysis
D. S. Raj (2000)
A comparison of on-line hemodiafiltration and high-flux hemodialysis: a prospective clinical study.
R. Ward (2000)
10.1046/J.1523-1755.2001.0590031134.X
Increased vascular growth in hemodialysis patients induced by platelet-derived diadenosine polyphosphates.
J. Jankowski (2001)
10.1053/AJKD.2001.21290
Mortality risk by hemodialyzer reuse practice and dialyzer membrane characteristics: results from the usrds dialysis morbidity and mortality study.
F. Port (2001)
10.1177/039139880102401004
Uremic Toxicity: Present State of the Art
R. Vanholder (2001)
10.1016/S0140-6736(01)07217-8
Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study
C. Zoccali (2001)
10.1046/J.1523-1755.2003.00912.X
Involvement of voltage- and ligand-gated Ca2+ channels in the neuroexcitatory and synergistic effects of putative uremic neurotoxins.
R. D'Hooge (2003)
10.1007/s00467-003-1071-y
Urea percentiles in children with chronic renal failure
G. Montini (2003)
10.1046/J.1523-1755.2003.00924.X
Review on uremic toxins: classification, concentration, and interindividual variability.
R. Vanholder (2003)
Effect of dialysis dose and membrane flux in maintenance hemodialysis.
F. Locatelli (2003)
10.1373/49.3.470
Toxicity of free p-cresol: a prospective and cross-sectional analysis.
R. De Smet (2003)
10.1097/01.ASN.0000096373.13406.94
Effects of high-flux hemodialysis on clinical outcomes: results of the HEMO study.
A. Cheung (2003)
10.1046/J.1523-1755.2003.00310.X
Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms.
B. Bammens (2003)
Removal of middle molecules and protein-bound solutes by Pediatr Nephrol (2008) 23:1211–1221 1219 peritoneal dialysis and relation with uremic symptoms
B Bammens (2003)
Removal of middle molecules and proteinbound solutes by
B Bammens (2003)
10.1093/NDT/GFH475
Interleukin-18 is a strong predictor of hospitalization in haemodialysis patients.
C. Chiang (2004)
10.1161/01.CIR.0000105764.22626.B1
Cardiovascular Effects of Systemic Nitric Oxide Synthase Inhibition With Asymmetrical Dimethylarginine in Humans
J. Kielstein (2004)
10.1111/J.1523-1755.2004.00399.X
The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair.
L. Dou (2004)
10.1111/J.1523-1755.2004.00961.X
In vitro evidence for immune activating effect of specific AGE structures retained in uremia.
G. Glorieux (2004)
10.1097/01.ASN.0000141041.71717.11
Plasma protein aspartyl damage is increased in hemodialysis patients: studies on causes and consequences.
A. Perna (2004)
10.1111/J.1523-1755.2004.00631.X
In vitro study of the potential role of guanidines in leukocyte functions related to atherogenesis and infection.
G. Glorieux (2004)
10.1186/1468-6708-6-8
Effect of increased convective clearance by on-line hemodiafiltration on all cause and cardiovascular mortality in chronic hemodialysis patients – the Dutch CONvective TRAnsport STudy (CONTRAST): rationale and design of a randomised controlled trial [ISRCTN38365125]
E. L. Penne (2005)
10.1111/J.1523-1755.2005.00238.X
Kinetic behavior of urea is different from that of other water-soluble compounds: the case of the guanidino compounds.
S. Eloot (2005)
10.1093/NDT/GFH813
Chronic kidney disease as cause of cardiovascular morbidity and mortality.
R. Vanholder (2005)
10.1093/NDT/GFH775
Pre-dilution on-line haemofiltration vs low-flux haemodialysis: a randomized prospective study.
C. Beerenhout (2005)
10.1038/nm1188
Uridine adenosine tetraphosphate: a novel endothelium- derived vasoconstrictive factor
V. Jankowski (2005)
10.1053/J.AJKD.2004.11.014
Dialyzer membrane permeability and survival in hemodialysis patients.
P. Chauveau (2005)
10.1681/ASN.2005030310
Removal of P-cresol sulfate by hemodialysis.
Andres W Martinez (2005)
10.1373/CLINCHEM.2005.050781
Gas chromatographic-mass spectrometric analysis for measurement of p-cresol and its conjugated metabolites in uremic and normal serum.
H. de Loor (2005)
23:1211–1221 line haemofiltration vs low-flux haemodialysis: a randomized prospective study
CH Beerenhout (2005)
Pre-dilution on- 1220
Ch Beerenhout (2005)
European Uremic Toxin Work Group (EUTox) (2005) Chronic kidney disease as cause of cardiovascular morbidity and mortality
R Vanholder (2005)
Pre-dilution online haemofiltration vs low-flux haemodialysis: a randomized prospective study
C H Beerenhout (2005)
10.1681/ASN.2005020132
Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study.
A. Cheung (2006)
10.1111/j.1542-4758.2006.01178.x
Clinical use of high‐efficiency hemodialysis treatments: Long‐term assessment
Juan P. Bosch (2006)
10.1038/SJ.KI.5000115
Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients.
B. Bammens (2006)
10.1681/ASN.2005101119
Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease.
S. Bode-Böger (2006)
10.1053/J.AJKD.2005.12.036
A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD.
G. Schulman (2006)
10.1053/J.AJKD.2005.09.031
Cerebrovascular disease in maintenance hemodialysis patients: results of the HEMO Study.
J. Delmez (2006)
10.1038/SJ.KI.5000447
Mortality risk for patients receiving hemodiafiltration versus hemodialysis: European results from the DOPPS.
B. Canaud (2006)
10.1080/10715760600818789
Human blood plasma advanced oxidation protein products (AOPP) correlates with fibrinogen levels
L. Selmeci (2006)
10.1159/000090411
Plasma Interleukin-18 Levels in Hemodialysis Patients: Increased by Dialysis Process and Association with Interleukin-6 and Tumor Necrotic Factor-α
C. Chiang (2006)
10.1053/J.AJKD.2006.11.026
Dialyzer membrane characteristics and outcome of patients with type 2 diabetes on maintenance hemodialysis.
V. Krane (2007)
10.1161/01.ATV.0000253889.09765.5f
Mass-Spectrometric Identification of a Novel Angiotensin Peptide in Human Plasma
V. Jankowski (2007)
10.1093/NDT/GFL584
P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production.
E. Schepers (2007)
10.1111/J.1525-1594.2007.00434.X
Inconsistency of reported uremic toxin concentrations.
N. Meert (2007)
10.1093/NDT/GFM022
EBPG guideline on dialysis strategies.
J. Tattersall (2007)
10.1093/NDT/GFM151
Review on uraemic solutes II--variability in reported concentrations: causes and consequences.
R. Vanholder (2007)
10.1093/EURHEARTJ/EHL455
The glomerular filtration rate in an apparently healthy population and its relation with cardiovascular mortality during 10 years.
W. van Biesen (2007)
10.1053/J.AJKD.2007.05.009
Complex compartmental behavior of small water-soluble uremic retention solutes: evaluation by direct measurements in plasma and erythrocytes.
S. Eloot (2007)
10.1016/J.CCA.2006.12.026
Overestimation of advanced oxidation protein products in uremic plasma due to presence of triglycerides and other endogenous factors.
A. Valli (2007)
10.1111/j.1538-7836.2007.02540.x
The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells
L. Dou (2007)
Pediatr Nephrol
(2008)
ESAO) published several reviews and position papers. Its current members are
Industry members are: Amgen; Baxter Health Care; Fresenius Medical Care
Wiecek
line haemofiltration vs low-flux haemodialysis: a randomized prospective study



This paper is referenced by
10.1155/2021/6639199
Reactive Oxygen Species and Their Involvement in Red Blood Cell Damage in Chronic Kidney Disease
K. Gwoździński (2021)
10.1016/j.msec.2021.111879
Fabrication of a novel nitrogen-containing porous carbon adsorbent for protein-bound uremic toxins removal.
Yunhong Liu (2021)
10.1002/9781119468769.HPCBM024
Development, Application and Future Trends of Pyrrolidone‐ and Caprolactam‐Based Materials in the Pharmaceutical Industry
D. Hood (2021)
10.3390/toxins13080551
Acute Kidney Injury and Organ Dysfunction: What Is the Role of Uremic Toxins?
J.I. Lara-Prado (2021)
10.3390/toxins13040246
Uremic Toxins and Blood Purification: A Review of Current Evidence and Future Perspectives
S. Magnani (2021)
10.3390/ijms22126196
Uremic Toxins and Their Relation with Oxidative Stress Induced in Patients with CKD
A. Pieniazek (2021)
10.1016/j.jpba.2020.113312
A rapid and sensitive method for simultaneous determination of eight protein-bound uremic toxins in human serum by UHPLC-MS/MS: application in assessing peritoneal dialysis.
Zhipeng Wang (2020)
10.1177/0391398820901826
Identification and characterisation of fluorescent substances in spent dialysis fluid
Jörn Meibaum (2020)
10.3390/cells9092039
Uremic Toxins Affect Erythropoiesis during the Course of Chronic Kidney Disease: A Review
E. Hamza (2020)
10.3390/cells9102303
Mutual Interaction of Clinical Factors and Specific microRNAs to Predict Mild Cognitive Impairment in Patients Receiving Hemodialysis
Jin-Bor Chen (2020)
10.2174/1573401315666190215111402
Pilot Study of Probiotic Supplementation on Uremic Toxicity and Inflammatory Cytokines in Chronic Kidney Patients
Cristina Techy Roth-Stefanski (2020)
10.1016/j.trsl.2020.09.001
Challenges of reducing protein-bound uremic toxin levels in chronic kidney disease and end stage renal disease.
Mónica Faria (2020)
10.34067/kid.0000272020
Cognitive Function and Uremic Toxins after Kidney Transplantation: An Exploratory Study
Elsemieke te Linde (2020)
10.3390/jcm9020437
Urinary Excretion of N1-methyl-2-pyridone-5-carboxamide and N1-methylnicotinamide in Renal Transplant Recipients and Donors
Carolien P J Deen (2020)
10.1111/1744-9987.13506
Medium cut‐off dialyzers in a large population of hemodialysis patients in Colombia: COREXH registry
A. Bunch (2020)
10.1016/j.tiv.2020.105013
Structural component changes of erythrocytes caused by oxidative stress generated by indoxyl sulfate.
A. Pieniazek (2020)
10.1016/j.tiv.2019.01.003
Uremic solutes modulate hepatic bile acid handling and induce mitochondrial toxicity.
K. Weigand (2019)
10.1111/aor.13355
Novel Extracorporeal Dialysis Circuit to Improve the Removal Efficiency of High and Middle Molecular Weight Toxins
Ali Poorkhali (2019)
10.1016/J.EKIR.2019.05.915
MON-125 Release of uremic retention solutes from protein binding by hypertonic predilution hemodiafiltration: a novel therapeutic approach
Falko Boehringer (2019)
10.31450/ukrjnd.3(63).2019.08
Cardiovascular complications in hemodialysis patients: current approaches to prolong and improve quality of patients’ life
F. O. Prusskiy (2019)
10.1590/2175-8239-JBN-2018-0033
The specific impact of uremic toxins upon cognitive domains: a review
Álvaro de Oliveira Franco (2019)
10.3389/fphys.2019.01108
Chronic Kidney Disease as a Risk Factor for Heart Failure With Preserved Ejection Fraction: A Focus on Microcirculatory Factors and Therapeutic Targets
J. van de Wouw (2019)
10.1016/j.neuro.2019.02.019
Indole-3 acetic acid increased risk of impaired cognitive function in patients receiving hemodialysis.
Y. Lin (2019)
10.1016/j.tiv.2019.03.029
The uremic toxin p-cresol promotes the invasion and migration on carcinoma cells via Ras and mTOR signaling.
Yueh-Han Hsu (2019)
10.1007/978-981-10-1100-9_6
Flux of Dialysis Membrane: Benefit and Risk
T. Tomo (2018)
10.1007/s00280-018-3583-y
Acceleration of carboxylesterase-mediated activation of irinotecan to SN-38 by serum from patients with end-stage kidney disease
H. Koide (2018)
Identification of biomarkers using-omics approach for the early detection of chronic kidney disease and its complications
V. Brunchault (2018)
10.1080/15257770.2018.1535122
Metabolism of 4-pyridone-3-carboxamide-1β-d-ribonucleoside (4PYR) in primary murine brain microvascular endothelial cells (mBMECs).
I. Pelikant-Małecka (2018)
10.1136/bmjopen-2018-022169
Randomised, open-label, multicentre trial comparing haemodialysis plus haemoperfusion versus haemodialysis alone in adult patients with end-stage renal disease (HD/HP vs HD): study protocol
W. Lu (2018)
10.1111/hdi.12702
Choosing a dialyzer: What clinicians need to know
S. Haroon (2018)
10.1042/CS20171107
Altered microbiome in chronic kidney disease: systemic effects of gut-derived uremic toxins.
W. Lau (2018)
10.1007/s10157-018-1577-z
Oral adsorbent AST-120 ameliorates gut environment and protects against the progression of renal impairment in CKD rats
A. Yoshifuji (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar